advanced CD33+ acute myeloid leukemia Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with

[1]  J. Korth-Bradley,et al.  Pharmacokinetics of Gemtuzumab Ozogamicin as a Single‐Agent Treatment of Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia , 2004, Journal of clinical pharmacology.

[2]  D. Reinhardt,et al.  Gemtuzumab Ozogamicin (Mylotarg®) in Children with Refractory or Relapsed Acute Myeloid Leukemia , 2004, Oncology Research and Treatment.

[3]  M. Berger,et al.  Licensure of Gemtuzumab Ozogamicin for the Treatment of Selected Patients 60 Years of Age or Older with Acute Myeloid Leukemia in First Relapse , 2002, Investigational New Drugs.

[4]  P. Richardson,et al.  Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. , 2003, Blood.

[5]  W. Tissing,et al.  Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. , 2003, Blood.

[6]  Leslie L Robison,et al.  Trends in leukemia incidence and survival in the United States (1973–1998) , 2003, Cancer.

[7]  I. Bernstein,et al.  Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) , 2002, Leukemia.

[8]  R. Arceci,et al.  What is the optimal therapy for childhood AML? , 2002, Oncology.

[9]  Irwin Hollander,et al.  Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. , 2002, Bioconjugate chemistry.

[10]  C. Civin,et al.  Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia. , 2001, Medical and pediatric oncology.

[11]  K. Wheatley,et al.  Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. , 2001, Blood.

[12]  I. Bernstein,et al.  Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. , 2001, Blood.

[13]  I. Bernstein,et al.  Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  X. H. Chen,et al.  Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  F. Berthold,et al.  Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Buckley,et al.  A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. , 2001, Blood.

[17]  R. Gray,et al.  Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial , 1998 .

[18]  R. Pieters,et al.  Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. , 1998, Blood.

[19]  D. Patel,et al.  Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  G. McDonald,et al.  Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients , 1993, Annals of Internal Medicine.

[21]  I. Bernstein,et al.  Expression of normal myeloid-associated antigens by acute leukemia cells. , 1986, Blood.